ORNL/CP-97929

Invited Paper, For, *Proceedings, 13th Radiochemical Conference*, Marianske Lazne, Czech Republic, April 19-24, 1998, *in press.*

CONF-980446--

PRODUCTION OF MEDICAL RADIOISOTOPES IN THE ORNL HIGH FLUX ISOTOPE REACTOR (HFIR) FOR CANCER TREATMENT AND ARTERIAL RESTENOSIS THERAPY AFTER PTCA

RECEIVED
JUN 25 1998
OSTI

[1]F. F. (Russ) KNAPP, Jr., [1]A. L. BEETS, [1]S. MIRZADEH, [2]C. W. ALEXANDER and [3]R. L. HOBBS

RECEIVED
MAY 14 1998
OSTI

[1] *Nuclear Medicine Group, Life Sciences Division*
[2] *Chemical Technology Division*
[2] *Research Reactors Division*
Oak Ridge National Laboratory (ORNL)
Oak Ridge, TN 37831-6229, U.S.A.

For reprints and correspondence contact: F. F. (Russ) Knapp, Jr., Group Leader, Nuclear Medicine, Oak Ridge National Laboratory (ORNL), Building 4501, Mail Stop 6229, P.O. Box 2008, Oak Ridge, TN 37831-6229; Tel. (423) 574-6225; FAX (423) 574-6226; E-mail <jkp@ornl.gov>.

DISTRIBUTION OF THIS DOCUMENT IS UNLIMITED

MASTER

Research at ORNL is supported by the U.S. Department of Energy (DOE), under contract DE-AC05-96OR22464 with Lockheed Martin Energy Research Corporation.

"The submitted manuscript has been authored by a contractor of the U.S. Government under contract No. DE-AC05-96OR22464. Accordingly, the U.S. Government retains a nonexclusive, royalty-free license to publish or reproduce the published form of this contribution, or allow others to do so, for U.S. Government purposes."